VSTM | tickerfilter.com

Fundamental analysis

19%

Profitability 25%

Dept financing 14%

Liquidity 75%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0.16%

1 Month

0.79%

3 Months

-32.24%

6 Months

-31.66%

1 Year

-10.63%

2 Year

-44.14%

Key data

Stock price

$6.39

P/E Ratio

N/A

DAY RANGE

$6.25 - $6.63

EPS

-$3.02

52 WEEK RANGE

$4.01 - $11.24

52 WEEK CHANGE

-$15.14

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

87.835 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

0.97

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,721,413

AVERAGE 30 VOLUME

$1,489,460

Company detail

CEO: Brian M. Stuglik
Region: US
Website: verastem.com
Employees: 50
IPO year: 2012

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

VSTM - Verastem, Inc.